Health plans walk a clinical tightrope when treating adolescents for depression.
Sipkoff
Martin
M
MSipkoff@ManagedCareMag.com
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000928:Antidepressive Agents / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation; D002648:Child; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005194:Family Practice; D005500:Follow-Up Studies; D006279:Health Maintenance Organizations; D006308:Health Systems Plans; D006801:Humans; D008329:Managed Care Programs; D011320:Primary Health Care; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics / Q000627:therapeutic use; D013405:Suicide / Q000706:statistics & numerical data; D013406:Suicide, Attempted; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors